Gore Gains CE Mark for Proprietary Heparin Surface for Treatment of Arterial Vascular Disease
January 13, 2009 -W.L. Gore and Associates today said it received CE Mark of its GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface in the European Union.
The GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface combines Gore’s propriety heparin surface with the performance of the GORE VIABAHN Endoprosthesis for the treatment of arterial vascular disease. The GORE VIABAHN Endoprosthesis is indicated for the endovascular grafting of peripheral arteries.
The company said the product uses end-point covalent bonding to keep the heparin anchored to the endoprosthesis surface over time. The end-point surface attachment technology preserves the heparin bioactive sites such that they remain free to interact with the blood without being consumed, the company said.
GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface (5 to 8mm devices) is available with a low-profile delivery system that gives interventionalists a more streamlined approach to re-line the peripheral arteries. The GORE VIABAHN Endoprosthesis is constructed with a durable, reinforced, biocompatible, ePTFE liner attached to an external nitinol stent structure. The company said the excellent flexibility of the GORE VIABAHN Endoprosthesis enables it to better traverse tortuous areas of the superficial femoral artery and conform more closely to the complex anatomy of the artery.
For more information: www.goremedical.com
More like this
- Gore Receives CE Mark for Longer Stent-Graft
- Stent Graft Relining System Offers Lower Delivery Profile
- FDA Approves Endoprosthesis on Lower Profile Delivery System
- FDA Clears Large Diameter GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
- Gore Receives FDA Clearance for Modified GORE VIABAHN Endoprosthesis